1. A method of decreasing the likelihood of a major adverse cardiac event (MACE) in a subject that has previously experienced an acute coronary syndrome (ACS) event comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors and a therapeutically effective amount of one or more statins to said subject.
2. The method of claim 1, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
3. The method of claim 1, wherein the first administration of said one or more sPLA2 inhibitors takes place within 96 hours of the occurrence or diagnosis of said ACS event.
4. The method of claim 1, wherein said administration of one or more sPLA2 inhibitors occurs one or more times daily for a maximum of 16 weeks.
5. The method of claim 2, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
6. The method of claim 5, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
7. The method of claim 1, wherein said one or more statins are selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, lovastatin, pravastatin, cerivastatin, fluvastatin, mevastatin, and pitavastatin, and a statin combination drug.
8. The method of claim 1, wherein said MACE is selected from one or more of the group consisting of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or unstable angina requiring urgent hospitalization.
9. A method of inhibiting inflammation in a subject that has previously experienced an acute coronary syndrome (ACS) event comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors and a therapeutically effective amount of one or more statins to said subject.
10. The method of claim 9, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
11. The method of claim 9, wherein the first administration of said one or more sPLA2 inhibitors takes place within 96 hours of the occurrence or diagnosis of said ACS event.
12. The method of claim 9, wherein said administration of one or more sPLA2 inhibitors occurs one or more times daily for a maximum of 16 weeks.
13. The method of claim 10, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
14. The method of claim 13, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
15. The method of claim 9, wherein said one or more statins are selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, lovastatin, pravastatin, cerivastatin, fluvastatin, mevastatin, and pitavastatin, and a statin combination drug.
16. The method of claim 9, wherein said administration of one or more sPLA2 inhibitors and one or more statins results in a decrease in one or more inflammatory markers selected from the group consisting of sPLA2, hs-CRP, and IL-6.
17. A method of lowering non-HDL cholesterol levels in a subject who has previously experienced an acute coronary syndrome (ACS) event comprising administering to said subject a therapeutically effective amount of one or more sPLA2 inhibitors and a therapeutically effective amount of one or more statins.
18. The method of claim 17, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
19. The method of claim 17, wherein the first administration of said one or more sPLA2 inhibitors takes place within 96 hours of the occurrence or diagnosis of said ACS event.
20. The method of claim 17, wherein said administration of one or more sPLA2 inhibitors occurs one or more times daily for a maximum of 16 weeks.
21. The method of claim 18, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
22. The method of claim 21, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
23. The method of claim 17, wherein said one or more statins are selected from the group consisting of atorvastatin, rosuvastatin, simvastatin, lovastatin, pravastatin, cerivastatin, fluvastatin, mevastatin, and pitavastatin, and a statin combination drug.
24. The method of claim 17, wherein said administration of one or more sPLA2 inhibitors and one or more statins results in a decrease in LDL levels.
25. The method of claim 24, wherein LDL levels are decreased to a target level selected from the group consisting of 100 mgdl or less, 70 mgdl or less, and 50 mgdl or less.
26. A method of treating a major adverse cardiac event (MACE) in a subject who has previously experienced an acute coronary syndrome (ACS) event comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors.
27. The method of claim 26, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
28. The method of claim 27, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
29. The method of claim 28, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
30. A method of treating acute coronary syndrome (ACS) in a subject in need thereof comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors.
31. The method of claim 30, wherein said subject has previously experienced an ACS event.
32. The method of claim 30, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
33. The method of claim 32, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
34. The method of claim 33, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
35. A method of treating a major adverse cardiac event (MACE) in a subject who has previously experienced an acute coronary syndrome (ACS) event comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors and a therapeutically effective amount of one or more statins.
36. The method of claim 35, wherein treatment of MACE results in a decrease in the likelihood of MACE occurrence.
37. The method of claim 35, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
38. The method of claim 37, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
39. The method of claim 38, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
40. A method of treating acute coronary syndrome (ACS) in a subject in need thereof comprising administering a therapeutically effective amount of one or more sPLA2 inhibitors and a therapeutically effective amount of one or more statins.
41. The method of claim 40, wherein said subject has previously experienced an ACS event.
42. The method of claim 40, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
43. The method of claim 42, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
44. The method of claim 43, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
45. A method of inhibiting inflammation in a subject who has previously experienced an acute coronary syndrome (ACS) event comprising administering to said subject a therapeutically effective amount of one or more sPLA2 inhibitors.
46. The method of claim 45, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
47. The method of claim 46, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
48. The method of claim 47, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
49. A method of lowering non-HDL cholesterol levels in a subject who has previously experienced an acute coronary syndrome (ACS) event comprising administering to said subject a therapeutically effective amount of one or more sPLA2 inhibitors.
50. The method of claim 49, wherein said one or more sPLA2 inhibitors comprise 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
51. The method of claim 50, wherein said prodrug is selected from the group consisting of a C1-C6 alkyl ester prodrug, an acyloxyalkyl ester prodrug, and an alkyloxycarbonyloxyalkyl ester prodrug.
52. The method of claim 51, wherein said C1-C6 alkyl ester is 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyacetic acid methyl ester.
53. A method of reducing the risk of a major adverse cardiac event (MACE) selected from the group consisting of death, myocardial infarction, stroke, and unstable angina requiring urgent hospitalization in a subject who has experienced or been diagnosed with an acute coronary syndrome (ACS) event within the past 96 hours comprising administering a therapeutically effective amount of 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof and a therapeutically effective amount of one or more statins, wherein 3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof is administered once or twice daily for a maximum of 16 weeks.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for fabricating a crystal fiber having different regions of polarization inversion, comprising:
(a) providing a source material;
(b) putting the source material into a fabricating apparatus; and
(c) forming the crystal fiber from the source material, wherein the diameter of the crystal fiber is less than 500 \u03bcm, and applying an external electric field on the grown crystal fiber during the growth procedure of the crystal fiber so as to induce micro-swing of the crystal of the crystal fiber for polarization inversion.
2. The method according to claim 1, wherein the fabricating apparatus is a laser heated pedestal growth (LHPG) apparatus.
3. The method according to claim 1, wherein the external electric field is an alternating current field.
4. The method according to claim 1, wherein the material of the source material is ferroelectric and is selected from the group consisting of lithium niobate (LiNbO3), lithium tantalate (LiTaO3), patassium titanyl phosphate (KTP) and a dopant therein.
5. The method according to claim 4, wherein the dopant is selected from the group consisting of the oxidation states of magnesium, zinc, yttrium, neodymium and erbium, and the mixture thereof.
6. The method according to claim 1, wherein the ratio of the displacement of the micro-swing of the crystal to the diameter of the crystal fiber is between 0.9 to 1.5.
7. The method according to claim 1, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to the ground, and the second metal electrode is connected to a first high-voltage source whose waveform is alternating square wave.
8. The method according to claim 1, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a second high-voltage source whose waveform is alternating square wave, the second metal electrode is connected to a third high-voltage source whose waveform is alternating square wave, and the phase of the waveform of the second high-voltage source is reverse to that of the third high-voltage source.
9. The method according to claim 1, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a fourth high-voltage source whose waveform is direct impulse wave, the second metal electrode is connected to a fifth high-voltage source whose waveform is direct impulse wave, and the waveform of the fifth high-voltage source shifts one-half cycle to that of the fourth high-voltage source
10. A method for fabricating a crystal fiber having different regions of polarization inversion, comprising:
(a) providing a source material;
(b) putting the source material into a fabricating apparatus; and
(c) forming the crystal fiber from the source material, and applying an external electric field on the grown crystal fiber during the growth procedure of the crystal fiber so as to induce micro-swing of the crystal of the crystal fiber for polarization inversion, wherein the ratio of the displacement of the micro-swing of the crystal to the diameter of the crystal fiber is between 0.9 to 1.5.
11. The method according to claim 10, wherein the fabricating apparatus is a laser heated pedestal growth (LHPG) apparatus.
12. The method according to claim 10, wherein the external electric field is an alternating current field.
13. The method according to claim 10, wherein the material of the source material is ferroelectric and is selected from the group consisting of lithium niobate (LiNbO3), lithium tantalate (LiTaO3), patassium titanyl phosphate (KTP) and a dopant therein.
14. The method according to claim 13, wherein the dopant is selected from the group consisting of the oxidation states of magnesium, zinc, yttrium, neodymium and erbium, and the mixture thereof.
15. The method according to claim 10, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to the ground, and the second metal electrode is connected to a first high-voltage source whose waveform is alternating square wave.
16. The method according to claim 10, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a second high-voltage source whose waveform is alternating square wave, the second metal electrode is connected to a third high-voltage source whose waveform is alternating square wave, and the phase of the waveform of the second high-voltage source is reverse to that of the third high-voltage source.
17. The method according to claim 10, wherein the external electric field is provided by a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a fourth high-voltage source whose waveform is direct impulse wave, the second metal electrode is connected to a fifth high-voltage source whose waveform is direct impulse wave, and the waveform of the fifth high-voltage source shifts one-half cycle to that of the fourth high-voltage source.
18. An apparatus for making a source material into a crystal fiber having different regions of polarization inversion, comprising:
a laser beam generator for generating a laser beam;
a beam splitter for splitting the laser beam into a generally annular beam;
a bending mirror for reflecting the annular beam from the beam splitter;
a paraboloidal mirror for reflecting the annular beam from the bending mirror, and focusing the annular beam on the molten zone between the source material and the crystal fiber; and
an electric field generating device disposed near the molten zone for providing an external electric field which is used for poling the crystal fiber and inducing micro-swing of the crystal of the crystal fiber.
19. The apparatus according to claim 18, wherein the diameter of the crystal fiber is less than 500 \u03bcm.
20. The apparatus according to claim 18, wherein the ratio of the displacement of the micro-swing of the crystal to the diameter of the crystal fiber is between 0.9 to 1.5.
21. The apparatus according to claim 18, wherein the electric field generating device comprises a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to the ground, and the second metal electrode is connected to a first high-voltage source whose waveform is alternating square wave.
22. The apparatus according to claim 18, wherein the electric field generating device comprises a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a second high-voltage source whose waveform is alternating square wave, the second metal electrode is connected to a third high-voltage source whose waveform is alternating square wave, and the phase of the waveform of the second high-voltage source is reverse to that of the third high-voltage source.
23. The apparatus according to claim 18, wherein the electric field generating device comprises a first metal electrode and a second metal electrode, wherein the first metal electrode is connected to a fourth high-voltage source whose waveform is direct impulse wave, the second metal electrode is connected to a fifth high-voltage source whose waveform is direct impulse wave, and the waveform of the fifth high-voltage source shifts one-half cycle to that of the fourth high-voltage source.